A novel Plasmodium vivax vaccine based on recombinant chimpanzee adenovirus ChAd63 and MVA expressing TRAP

Karolis Bauza,Oliver Billker,Arturo Reyes-Sandoval,Adrian Vs Hill

doi:10.1186/1475-2875-11-s1-o49

Karolis Bauza, Oliver Billker + Show 2 more

Open Access

https://doi.org/10.1186/1475-2875-11-s1-o49

Copy DOI

Abstract

Background P. vivax is the most geographically widespread human malaria and is considered to be the most prevalent form in some regions of Latin America, Central and South-East Asia, accounting for up to 390 million clinical infections every year and an estimated 2.6 billion people being at risk of infection with P. vivax [1,2]. An effective vaccine against this protozoan would have a major global impact on the disease burden [3]. Modified Vaccinia Ankara (MVA) and the chimpanzee adenovirus ChAd63 are two clinically relevant viral vectors that have been shown to induce strong and protective antibody and T-cell responses against P. falciparum TRAP, both in pre-clinical studies and clinical trials [4-7].

Highlights

P. vivax is the most geographically widespread human malaria and is considered to be the most prevalent form in some regions of Latin America, Central and South-East Asia, accounting for up to 390 million clinical infections every year and an estimated 2.6 billion people being at risk of infection with P. vivax [1,2]
The strong immunogenicity and protective efficacy elicited by the recombinant ChAd63 and Modified Vaccinia Ankara (MVA) viruses expressing PvTRAP indicate that this vaccine approach has a good potential to be tested in clinical trials in the near future
Materials and methods We developed recombinant ChAd63 and MVA vectors expressing P. vivax TRAP (PvTRAP), which were used to assess T-cell and antibody responses upon sequential immunisation of mice

Summary

Introduction

P. vivax is the most geographically widespread human malaria and is considered to be the most prevalent form in some regions of Latin America, Central and South-East Asia, accounting for up to 390 million clinical infections every year and an estimated 2.6 billion people being at risk of infection with P. vivax [1,2]. Conclusions The strong immunogenicity and protective efficacy elicited by the recombinant ChAd63 and MVA viruses expressing PvTRAP indicate that this vaccine approach has a good potential to be tested in clinical trials in the near future.

Results

Conclusion